secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2024-02-07T23:59:59+00:00
Accession:  0001193125-24-025941
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase receives FDA guidance on 505(b)(2) path for IkT-001Pro; Parkinson's trial enrolling 51 patients
--------------------------------------------------------------------------------

- FDA pre-NDA meeting on Jan 19, 2024: acknowledges 505(b)(2) pathway appropriate for IkT-001Pro in blood/gastrointestinal cancers.
- Bioequivalence shows 600mg/800mg IkT-001Pro similar to 400mg/600mg imatinib; FDA advises evaluating doses up to 800mg.
- Company to seek all 11 imatinib indications; must conduct gut transporter studies and use-related risk analysis.
- Risvodetinib 201 Trial: 32 sites open, 51 enrolled, 23 completed 12 weeks, 10 mild/moderate AEs reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312524025941/0001193125-24-025941-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312524025941/d678628d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-025941

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer